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Abstract
Hepatitis E virus (HEV) can cause chronic infections in immuno-
compromised hosts. Viral kinetics in plasma and stools are poorly
understood, particularly during antiviral treatment. Prolonged faecal
shedding may be a concern for transmission. We describe HEV
kinetics in an immunocompromised patient with prolonged faecal
shedding despite undetectable viraemia on ribavirin treatment.
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Hepatitis E virus (HEV) is a major cause of acute viral hepatitis
worldwide. Four main genotypes have been documented, each
of them with different geographical distributions. Hepatitis E
virus is transmitted by the faecal-oral route and some
genotypes have a large animal reservoir. Hepatitis E virus
infections are classically considered to be acute and self-lim-
ited. In immunocompetent patients, faecal shedding and
viraemia cease several days after the primary infection [1,2].
Protracted or chronic infections, however, have been
described in immunocompromised patients such as HIV-in-
fected patients [3], solid organ transplant recipients [4] and
haematological or oncological patients, particularly recipients
of stem cell transplants [5,6]. Persistent HEV infection can
contribute to the development of hepatic cirrhosis [5,7].
Treatment with ribavirin (RBV) and/or pegylated interferon
alpha (peg-IFN-a) may be effective in these cases [8,9].
Transmission may be a concern in the setting of this
prolonged viral shedding. The Centers for Disease Control
and Prevention (CDC) issued guidelines for isolation precau-
tions in 2007 recommending standard isolation measures for
hospitalized patients with HEV infection and the use of contact
precautions for diapered or incontinent individuals for the
duration of illness [10]. No speciﬁc recommendation is
provided regarding patients with chronic infection. Moreover,
most of them are asymptomatic, so the duration of illness
cannot be established by clinical parameters.
Currently, little is known about HEV long-term dynamics in
blood and stools when antiviral and/or immunomodulatory
therapy is introduced in patients with chronic infection. We
describe the kinetics of HEV in plasma and stools during a
1-year period in an immunocompromised patient and the
impact of antiviral therapy.
Hepatitis E virus ribonucleic acid (RNA) detection in plasma
was performed by an in-house quantitative real-time
reverse-transcriptase polymerase chain reaction (RT-PCR)
modiﬁed from the technique described by Abravanel et al.
[11]. The same assay was conducted as a semi-quantitative assay
in stools; 500 lL stool samples were resuspended in 5 mL of
PBS (Phosphate Buffer Saline, Dulbecco s/Ca,Mg, GIBCO,
14190), vortexed and centrifuged at 3000 rpm for 10 min.
Stool supernatant was extracted in parallel with plasma (Easy-
Mag, BioMerieux, Craponne, France). Results were expressed as
CT (cycle threshold). The limit of detection was 37.5 CT.
One-step RT-PCR (Quantitect Probe RT-PCR kit, Qiagen,
204445, Venlo, Netherlands) was carried out on StepOne Plus
(Applied Biosystems, Foster City, CA, USA) with the following
primers: forward: 50-GGTGGTTTCTGGGGTGAC-30, reverse:
50-AGGGGTTGGTTGGATGAA-30 and probe: VIC-TGATTC-
TCAGCCCTTCGC-TAMRA, and the following conditions:
50°C – 300//95°C – 150//45x “94°C – 150’ + 60°C – 10. The
quantitative RT-PCR in plasma was conducted using a standard
curve ran in parallel (plasmids, calibrated with WHO HEV
International Standards) and results were expressed in IU/mL
(international units permL). Limit of detectionwas 2.3 log IU and
linearity was observed between 2.3 and 7 log IU for HEV load.
Genotyping was not performed. Clinical and epidemiological
information was obtained both prospectively and retrospec-
tively from the patient’s clinical chart. Data on other potential
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related cases of HEV infection were obtained from the
laboratory database and clinical charts.
A 53-year-old female patient with a history of chronic
lymphocytic leukaemia (CLL) diagnosed in 2003, treated by
several lines of immunosuppressive therapy since 2007 and
splenectomized, was noted to have transaminases at ten times
the upper limit of normal in September 2011. Serological tests
were negative for hepatitis A (HAV), B (HBV) and C (HCV)
viruses; HBV DNA and HCV RNA were undetectable. An
abdominal computed tomography scan showed a morpholog-
ically normal liver. High transaminases persisted and were
ﬁnally deemed likely to result from drug toxicity. The patient
declined liver biopsy. In January 2012, HEV infection was
diagnosed, with high plasma viral RNA loads (>7 log UI/mL) as
well as HEV RNA in stools (Fig. 1). The CD4 cell count at this
time was 182 cells/lL (9%). Speciﬁc anti-HEV IgM was positive
and IgG negative; IgG seroconversion was documented
9 months later. This delayed seroconversion was attributed
to immunosuppression. Retrospective analyses of stored
plasma samples revealed positive HEV viraemia since Septem-
ber 2011, indicating a chronic HEV infection for at least
6 months. Given the elevated liver function tests, ribavirin
treatment was started in April 2012 at a dose of 400 mg bid,
and was followed by a progressive decrease in plasma and
stool HEV load. Transaminase levels signiﬁcantly improved to
two to three times the upper limit of normal. After 48 weeks
of RBV therapy, HEV was undetectable in plasma but detected
in stools at lower levels (Fig. 1). Ribavirin therapy was
continued. Episodes of transient HEV viraemia were docu-
mented after therapy with alemtuzumab. At present, RBV
therapy is ongoing and well tolerated. HEV is no longer
detectable in plasma, but persists in stool samples. Transam-
inases remained at normal levels.
None of the documented HEV seroconversions between
2011 and 2013 in our institution could be related to this
patient.
Hepatitis E virus has been classically considered an acute
infection, with severe presentations in pregnant women
leading in some cases to fulminant hepatitis [1,2]. Chronic
infections have, however, been identiﬁed in patients with
decreased cell-mediated immunity, leading to persistent rep-
lication and even liver cirrhosis. RBV, peg-IFN-a or both have
been proposed as therapy [3–9]. In cases in which RBV was
given, doses ranged between 600 and 800 mg/day or were
weight-adapted at 12 mg/kg [8,12], although a standard dosing
strategy has not been deﬁnitively established. The viral
long-term kinetics and clinical manifestations, including faecal
shedding, have not been thoroughly described. Prolonged
shedding becomes a concern, particularly when such patients
require hospitalization on a unit containing other immunosup-
pressed patients. In our patient, it is very probable that faecal
shedding was already occurring during the 6 months preceding
the diagnosis. Indeed, HEV RNA has likely been present in
stools for more than 24 months. It must be emphasized that,
despite the rapid initial decline in HEV viraemia, with a 5-log
decrease in less than 2 months, 6 months passed before
plasma levels became undetectable, which is longer than
previously reported. No speciﬁc source of exposure could be
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FIG. 1. HEV kinetics in an immunosuppressed, chronically infected patient receiving long-term rivabirin therapy and several months of
alemtuzumab. HEV, hepatitis E virus; RBV, ribavirin; CT, threshold cycle; LOD, limit of detection.
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identiﬁed for this case; the patient had no corresponding travel
history or other risks.
It could be hypothesized that RBV levels were high enough
to inhibit replication in the liver, but not in the gastrointestinal
tract. Although RBV levels were not measured in our patient,
the dose administered is consistent with those reported in the
literature. Mechanisms of inhibition of HEV replication by RBV
are not completely understood and to our knowledge there is
currently no test to evaluate potential resistance to RBV. Both
swine and human cell lines are permissive of HEV replication in
vitro [13,14], but little is known about the replicating target
cells in humans in vivo. In the swine model, the small bowel and
colon are the main sites of extra-hepatic replication, but
whether replication also occurs via the enteric cells of
gut-associated lymphoid tissue (GALT) remains unclear [15].
It is also interesting that HEV viraemia recurred in our patient
in parallel with treatment with alemtuzumab, a powerful
immunosuppressant anti-CD52 monoclonal antibody targeting
mature lymphocytes. In this case, liver biopsy was not
performed early in the clinical course, and later was no longer
indicated, as the diagnosis was conﬁrmed by plasma HEV
detection and liver imaging revealed no abnormalities.
We provide an original, detailed description of HEV dynamics
in plasma and stools in the presence of ribavirin therapy. Such
persistent viral replication has never been described, particularly
in patients who have achieved undetectable plasma HEV levels
on antiviral therapy; prolonged RBV therapy may be required in
chronically immunosuppressed patients, although therapeutic
drug monitoring might help to establish the correct dose.
Strategies for infection control in this vulnerable—and growing
—population have not been developed yet. Clinicians must be
aware of the possibility of chronic HEV infection in immuno-
compromised patients with elevated liver function tests, even
among those without the classic history of travel to endemic
countries. These results suggest that both HEV plasma and stool
loads should be routinely measured to assist in determination of
the duration of antiviral therapy. In special cases, liver biopsymay
be considered to evaluate possible persistence of hepatic viral
replication when patients achieve undetectable levels in plasma
and stools. The prolonged shedding detected in our patient also
highlights the need to develop infection control strategies for
chronic infections, particularly given the context of signiﬁcant
immunosuppression as well as frequent gastrointestinal side--
effects related to chemotherapy or antibiotics in this population.
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